MLICM
APRE icon

Metropolitan Life Insurance Company (MetLife)’s Aprea Therapeutics APRE Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-117
Closed -$90.4K – 2558
2020
Q2 		$90.4K Hold
117
– – ﹤0.01% 2314
2020
Q1 		$81K Buy
+117
New +$85.8K ﹤0.01% 2164

Other funds holding APRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s APRE Position: Q3 2020 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Aprea Therapeutics (APRE) in Q3 2020, closing a stake of 117 shares — an estimated $90.4K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in APRE in Q1 2020 and held it in 2 quarters. The position peaked at $90.4K in Q2 2020. 64 funds tracked by Wall St. Rank hold APRE as of Q3 2020.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Aprea Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 117 Aprea Therapeutics shares in Q3 2020, an estimated $90.4K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Aprea Therapeutics in Q1 2020 and held it in 2 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Aprea Therapeutics position peaked at $90.4K in Q2 2020.
  • 64 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q3 2020.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q3 2020, filed 13 Nov 2020.